Efficacy of Triple Antiplatelet Therapy (Aspirin, Clopidogrel, and Cilostazol) in Cerebral Infarction Presenting with Hemiplegia: A Case Report and Critical Appraisal of Current Evidence

This is a preview and has not been published.

Efficacy of Triple Antiplatelet Therapy (Aspirin, Clopidogrel, and Cilostazol) in Cerebral Infarction Presenting with Hemiplegia: A Case Report and Critical Appraisal of Current Evidence

Authors

  • Muhammad Yunus Amran Division of Interventional Neurology and Neuroendovascular Therapy, Department of Neurology, Faculty of Medicine, Hasanuddin University; Brain Centre, Dr. Wahidin Sudirohusodo General Hospital; Hasanuddin University Teaching Hospital, Makassar, Indonesia. https://orcid.org/0000-0001-5079-7490
  • M Akbar Yunus Department of Neurology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. https://orcid.org/0009-0007-1705-4856
  • M Fajrin Hidayah Department of Neurology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia. https://orcid.org/0009-0008-2947-4513
  • Fitri Jafani La’biran Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
  • Siti Giranti Ardilia Gunadi Department of Neurology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.
  • Irbab Hawari Department of Neurology, Al- Azhar Islamic University, Mataram, Indonesia.

Keywords:

Cerebral infarction, Triple antiplatelet therapy, bleeding intracranial, hemiplegic motor deficit

Abstract

Cerebral infarction, a type of stroke, occurs when blood vessels in the brain become occluded. Triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) has been used to prevent recurrent episodes in patients with cerebral infarction; however, it carries a risk of bleeding. In this case report, we demonstrated the effectiveness of triple antiplatelet therapy in a patient with cerebral infarction and hemiplegic motor deficits. A 38-year-old man presented with paralysis of the right side of his body and slurred speech after resting for 14 hours before hospital admission. He denied prior head trauma, fever, headache, nausea, or loss of consciousness. There was no history of hypertension, diabetes mellitus, or heart disease, but the patient reported smoking 24 cigarettes daily. A head CT scan revealed an infarction in the external capsule and left corona radiata. Cerebral angiography showed occlusion of the left lenticulostriate artery, a branch of the middle cerebral artery (MCA) at the M1 segment. The patient was treated with citicoline, mecobalamin, atorvastatin, and ranitidine, in addition to triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol). After eight days of treatment, the motor strength in the right upper and lower extremities showed significant improvement. The use of triple antiplatelet therapy in cerebral infarction remains a controversial topic due to the associated risk of major bleeding. However, in this case, the administration of triple antiplatelet therapy, guided by the TARDIS study, resulted in a favorable clinical outcome. 

Author Biographies

Muhammad Yunus Amran, Division of Interventional Neurology and Neuroendovascular Therapy, Department of Neurology, Faculty of Medicine, Hasanuddin University; Brain Centre, Dr. Wahidin Sudirohusodo General Hospital; Hasanuddin University Teaching Hospital, Makassar, Indonesia.

Division of Interventional Neurology and Neuroendovascular Therapy, Department of Neurology, Faculty of Medicine,   Hasanuddin University, Makassar, Indonesia.

Brain Centre, Dr. Wahidin Sudirohusodo General Hospital, Makassar, Indonesia.

Hasanuddin University Teaching Hospital, Makassar, Indonesia.

M Akbar Yunus, Department of Neurology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.

Department of Neurology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

M Fajrin Hidayah, Department of Neurology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.

Department of Neurology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Fitri Jafani La’biran, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.

Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Siti Giranti Ardilia Gunadi, Department of Neurology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia.

Department of Neurology, Faculty of Medicine, Hasanuddin University, Makassar, Indonesia

Irbab Hawari, Department of Neurology, Al- Azhar Islamic University, Mataram, Indonesia.

Department of Neurology, Al- Azhar Islamic University, Mataram, Indonesia

References

Tadi P, Lui F. Acute Stroke. [Updated 2023 Feb 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK535369/

Kuriakose D, Xiao Z. Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives. Int J Mol Sci. 2020;21(20):7609. Published 2020 Oct 15. doi:10.3390/ijms21207609

Lucotti S, Cerutti C, Soyer M, et al. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. J Clin Invest. 2019;129(5):1845-1862. Published 2019 Mar 25. doi:10.1172/JCI121985

Balinski AM, Preuss CV. Cilostazol. [Updated 2022 Sep 21]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK544363/

Beavers CJ, Naqvi IA. Clopidogrel. [Updated 2022 Jul 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470539/

Andrade JG, Deyell MW, Khoo C, Lee M, Humphries K, Cairns JA. Risk of bleeding on triple antithrombotic therapy after percutaneous coronary intervention/stenting: a systematic review and meta-analysis. Can J Cardiol. 2013;29(2):204-212. doi:10.1016/j.cjca.2012.06.012

Adibhatla RM, Hatcher JF, Dempsey RJ. Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem. 2002;80(1):12-23. doi:10.1046/j.0022-3042.2001.00697.x

Gupta JK, Sana QS. Potential benefits of methylcobalamin: a review. Austin J Pharmacol Ther. 2015;3(3):1076. ISSN: 2373-6208.

Zhao J, Zhang X, Dong L, Wen Y, Cui L. The many roles of statins in ischemic stroke. Curr Neuropharmacol. 2014;12(6):564-574. doi:10.2174/1570159X12666140923210929

Morgan KA, Ahlawat R. Ranitidine. [Updated 2022 Dec 11]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK532989/

Benjamin EJ, Muntner P, Alonso A, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association [published correction appears in Circulation. 2020 Jan 14;141(2):e33. doi: 10.1161/CIR.0000000000000746.]. Circulation. 2019;139(10):e56-e528. doi:10.1161/CIR.0000000000000659

Hurford R, Sekhar A, Hughes TAT, Muir KW. Diagnosis and management of acute ischaemic stroke. Pract Neurol. 2020;20(4):304-316. doi:10.1136/practneurol-2020-002557

Kamarova M, Baig S, Patel H, et al. Antiplatelet Use in Ischemic Stroke. Ann Pharmacother. 2022;56(10):1159-1173. doi:10.1177/10600280211073009

Iqbal AM, Lopez RA, Hai O. Antiplatelet Medications. In: StatPearls. Treasure Island (FL): StatPearls Publishing; November 7, 2022.

Willmot M, Zhao L, Heptinstall S, Bath P. Triple antiplatelet therapy for secondary prevention of recurrent ischemic stroke. J Stroke Cerebrovasc Dis. 2004;13(3):138-140. doi:10.1016/j.jstrokecerebrovasdis.2004.03.001

Sprigg N, Gray LJ, England T, et al. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. PLoS One. 2008;3(8):e2852. Published 2008 Aug 6. doi:10.1371/journal.pone.0002852

TARDIS Trial Investigators, Krishnan K, Beridze M, et al. Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388). Int J Stroke. 2015;10(7):1159-1165. doi:10.1111/ijs.12538

Geeganage C, Wilcox R, Bath PM. Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis. BMC Med. 2010;8:36. Published 2010 Jun 16. doi:10.1186/1741-7015-8-36

Maguida G, Shuaib A. Collateral Circulation in Ischemic Stroke: An Updated Review. J Stroke. 2023;25(2):179-198. doi:10.5853/jos.2022.02936

Ban M, Han X, Bao W, Zhang H, Zhang P. Evaluation of collateral status and outcome in patients with middle cerebral artery stenosis in late time window by CT perfusion imaging. Front Neurol. 2022;13:991023. Published 2022 Sep 13. doi:10.3389/fneur.2022.991023

Okyere B, Mills WA 3rd, Wang X, et al. EphA4/Tie2 crosstalk regulates leptomeningeal collateral remodeling following ischemic stroke. J Clin Invest. 2020;130(2):1024-1035. doi:10.1172/JCI131493

Bath PM, Woodhouse LJ, Appleton JP, et al. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT. Health Technol Assess. 2018;22(48):1-76. doi:10.3310/hta22480

Kim TJ, Lee JS, Yoon JS, et al. Multiple Antiplatelet Therapy in Ischemic Stroke Already on Antiplatelet Agents Based on the Linked Big Data for Stroke. J Korean Med Sci. 2023;38(38):e294. Published 2023 Sep 25. doi:10.3346/jkms.2023.38.e294

Wu Z, Liu AF, Zhou J, et al. The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. J Neurointerv Surg. 2019;11(4):352-356. doi:10.1136/neurintsurg-2018-013987

Woodhouse LJ, Appleton JP, Christensen H, et al. Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. Sci Rep. 2023;13(1):11717. Published 2023 Jul 20. doi:10.1038/s41598-023-38474-2

Sprigg N, Gray LJ, England T, et al. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility. PLoS One. 2008;3(8):e2852. Published 2008 Aug 6. doi:10.1371/journal.pone.0002852

Jonas S, Grieco G. Potential value of triple antiplatelet therapy for secondary stroke prevention. Stroke. 2003;34(10):e182-e183. doi:10.1161/01.STR.0000092896.70446.87

Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in BMJ 2002 Jan 19;324(7330):141]. BMJ. 2002;324(7329):71-86. doi:10.1136/bmj.324.7329.71

Wang MT, Tsai CK, Kuo SH, et al. The Dipyridamole Added to Dual Antiplatelet Therapy in Cerebral Infarction After First Acute Myocardial Infarction: A Nationwide, Case-Control Study. Front Neurol. 2018;9:1003. Published 2018 Nov 27. doi:10.3389/fneur.2018.01003

Liu L, Huang J, Zhang X, Tang X. Efficacy and safety of triple therapy versus dual antiplatelet therapy in patients with atrial fibrillation undergoing coronary stenting: A meta-analysis. PLoS One. 2018;13(6):e0199232. Published 2018 Jun 19. doi:10.1371/journal.pone.0199232

Gwyn JCV, Thomas MR, Kirchhof P. Triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention: a viewpoint. Eur Heart J Cardiovasc Pharmacother. 2017;3(3):157-162. doi:10.1093/ehjcvp/pvx002

How to Cite

1.
Amran MY, Yunus MA, Hidayah MF, La’biran FJ, Gunadi SGA, Hawari I. Efficacy of Triple Antiplatelet Therapy (Aspirin, Clopidogrel, and Cilostazol) in Cerebral Infarction Presenting with Hemiplegia: A Case Report and Critical Appraisal of Current Evidence. Acta Biomed.:16931. doi:10.23750/abm.vi.16931

How to Cite

1.
Amran MY, Yunus MA, Hidayah MF, La’biran FJ, Gunadi SGA, Hawari I. Efficacy of Triple Antiplatelet Therapy (Aspirin, Clopidogrel, and Cilostazol) in Cerebral Infarction Presenting with Hemiplegia: A Case Report and Critical Appraisal of Current Evidence. Acta Biomed.:16931. doi:10.23750/abm.vi.16931